Showing 1–12 of 175 results

  • Myelodysplastic syndrome

    5-azacytidine

    [product name] RONG

    [English common name]5-azacytidine

    [Chinese common name]5-azacytidine

    [English name]4-Amino-1-(β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one

    [Chinese other name]

    [Indications] for the treatment of ulcerative colitis, Crohn's disease; suppositories for the treatment of ulcerative proctitis, can also be combined with mesalazine tablets.

    [Usage and Dosage] Oral: Adult, ulcerative colitis (acute attack): 4 times a day, 1g each time; maintenance treatment, 3 times a day, 0.5g each time.
    Crohn's disease: 4 times a day, 1g each time. For children over 2 years old, take 20-30mg per kilogram of body weight per day, in divided doses.
    Suppository: Adult, 1-2 times a day, 1 suppository each time. Children over the age of two, follow the doctor's advice.

    [Storage] The tablets should be stored at room temperature (15-25 °C) and should not be taken after the expiration date. Suppositories should be stored at room temperature (15-25 °C) in the original package and should not be used after the expiration date.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Breast cancer

    Ado-trastuzumab

    【Product name】Kadcyla

    [English common name]Ado-trastuzumab emtansine

    [Chinese common name]Ado-trastuzumab

    [English name]

    [Chinese other name]

    [indications] metastaticBreast cancer: This product is suitable for HER2-positive metastatic breast cancer: metastatic breast cancer that has received one or more chemotherapy regimens as a single drug; combined with paclitaxel or docetaxel for metastasis without chemotherapy Breast cancer patients.
    Adjuvant therapy for breast cancer: This product is suitable for the adjuvant treatment of HER2 overexpressing breast cancer after surgery, adjuvant chemotherapy with anthracyclines and radiotherapy (if applicable).
    Metastatic gastric cancer: This product is combined with capecitabine or 5-fluorouracil and cisplatin for patients with metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have not received HER2 overexpression for the treatment of metastatic disease.
    Trastuzumab can only be used in patients with metastatic gastric cancer with HER2 overexpression, and HER2 overexpression is defined as IHC3+ or IHC2+/FISH+ results obtained using validated assays.

    [Usage and Dosage] Please fully dilute the reconstituted drug after the requirement of 'infusion preparation'.
    Do not push or push the vein quickly.
    HER2 testing should be performed prior to treatment with this product.
    The use of any other biological substitutes requires the consent of the prescribing physician.
    This product should be administered by intravenous infusion.
    Metastatic breast cancer
    Weekly dosing schedule
    Initial load dose: It is recommended that the initial load of this product is 4mg/kg. Intravenous infusion for more than 90 minutes.
    Maintenance dose: This product is recommended to be used at a dose of 2 mg/kg per week. If the initial load is tolerable, the dose can be infused intravenously for 30 minutes. Maintain treatment until disease progression.

    [Storage] Store in the refrigerator (2 ° C – 8 ° C).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Multiple myeloma

    A-protease inhibitor

    【Product name】Zemaira

    [English common name]a lpha1-proteinase

    [Chinese common name]A-protease inhibitor

    [English name]

    [Chinese other name]

    [Indications] It is used to alleviate lung damage in patients with severe diseases.

    [Usage and Dosage] The recommended dose is 60 mg per kg of body weight, once a week. The infusion should last for about 15 minutes.

    [Storage] ZemairaTM remains stable for the life of the label when stored at temperatures up to 25 ° C (77 ° F). Avoid freezing, otherwise the container of the thinner may be damaged.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Multiple myeloma

    Marizomib

    【Product name】

    [English common name]Marizomib

    [Chinese common name]

    [English name]NPI-0052, NPI0052, NPI-0052, UNII-703P9YDP7F

    [Chinese other name]

    [indications]

    【Dosage】

    [Storage]

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Pancreatic cancer

    Necuparanib

    【Product name】

    [English common name] Necuparanib

    [Chinese common name]

    [English name]

    [Chinese other name]

    [indications]

    【Dosage】

    [Storage]

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Multiple sclerosis

    Ocrelizumab

    [product name] ocreves

    [English common name] ocrelizumab

    [Chinese common name]

    [English name]

    [Chinese other name]

    [Indications] Ocrevus is a treatmentMultiple sclerosisThe drug – Multiple Sclerosis is a neurological inflammatory disease that can cause symptoms such as weakness, difficulty walking and vision problems.
    Ocrevus is used in two groups of patients: adults with relapsing multiple sclerosis (RMS) who have a sudden onset (relapse) and then have a mild or asymptomatic period; with primary progressive multiple sclerosis (PPMS) Adults, as time goes on, the symptoms will gradually deteriorate.
    Ocrevus contains the active substance ocrelizumab.

    [Usage and Dosage] Ofcrevus enters the vein as an infusion (drop). The first two infusions were separated for two weeks and then infused every six months. Other medications (corticosteroids and antihistamines) are given to patients prior to each infusion to help prevent potentially dangerous reactions. If a reaction occurs during the infusion, a slower response can be stopped or given. Patients should be monitored during the infusion process and monitored at least one hour thereafter, and facilities that manage severe reactions should be readily available.

    [Storage]

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Non-myeloid malignancy

    TBO-cell colony stimulating factor

    【Product name】Granix

    [English common name]Tbo-filgrastim

    [Chinese common name]TBO-Fogstone

    [English name]

    [Chinese other name]

    [indications]
    Recombinant human granulocyte colony-stimulating factor injection:
    1. Cancer chemotherapy and other reasons lead toNeutropeniaCancer patients use myelosuppressive chemotherapy drugs, especially after strong bone marrow deprivation chemotherapy, injection of this product can help prevent the occurrence of neutropenia, reduce the degree of neutropenia, shorten the granulocyte The duration of the deficiency accelerates the recovery of granulocyte counts, thereby reducing the risk of fever associated with infection.
    2. Promote an increase in the number of neutrophils after bone marrow transplantation.
    3. Neutropenia caused by myelodysplastic syndrome, neutropenia caused by aplastic anemia, congenital, idiopathic neutropenia, myelodysplastic syndrome with neutral Agranulocytopenia, periodic neutropenia.
    TBO-granulocyte colony-stimulating factor pre-filled syringe: GRANIX (TBO-granulocyte colony-stimulating factor) is a clinically significant anti-myeloablative disease with the incidence of myelosuppression with febrile neutropenia The duration of severe neutropenia in cancer drugs is indicative of leukocyte growth factor.

    【Dosage】
    Recombinant human granulocyte colony-stimulating factor injection: The product is administered subcutaneously or intravenously 24 to 48 hours after the end of administration of the chemotherapy drug, once a day. The dosage and time of administration of this product should be determined according to the intensity of chemotherapy and the degree of neutrophil decline. For patients with greater chemotherapy intensity or decreased granulocyte count, it is more suitable to continue to take the drug for more than 7 days at a dose of 2.5 μg/kg body weight/day until the neutrophil is restored to 5000/mm3; if the dose of chemotherapy drug is used Lower, estimated to cause less severe myelosuppression, consider using a lower dose to prevent neutropenia, 1.25μg / kg body weight / day dose to the neutrophil number is stable in a safe range, Patients with significantly reduced neutrophils after chemotherapy (neutrophil count <1000/mm3).
    TBO-granulocyte colony stimulating factor prefilled syringe:
    Recommended dose: 5 micrograms per kilogram per day for subcutaneous injection.
    Myelosuppressive chemotherapy was administered no earlier than 24 hours after the first dose was administered. Do not give chemotherapy for the first 24 hours.

    [Storage]
    Recombinant human granulocyte colony-stimulating factor injection: sealed and preserved.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Congenital factor XIII deficiency , hemophilia

    Human coagulation factor XIII

    【Product name】Corifact

    [English common name]Factor XIII concentrate

    [Chinese common name]Human coagulation factor XIII concentrate

    [English name]

    [Chinese other name]

    [indications]Congenital factor XIII deficiencyThe patient's hemorrhage.

    [Usage and dosage] is only for intravenous use. Formulated before use.
    Initial dose
    (1) 40 international units (units) per kilogram of body weight
    (2) Dosage rate should not exceed 4 mL per minute
    Subsequently administered
    (1) The application of the recent glutathione FXIII activity level was used to guide administration, and the dosing level was maintained at 5% to 20% every 28 days (4 weeks). It is recommended that the FXIII activity level be <5% or >20%, and the patient's clinical condition should be adjusted by ±5 units per kg of drug administration.
    (2) Dosing adjustments should be guided according to the specific analysis used to determine FXIII levels. Table 1 below is an overview of an example of a dose adjustment using Berichrom® activity analysis.
    Preparation and preparation
    (1) The storage vial is in the original box and in the refrigerator at 2-8 ° C (36-46 ° F). Do not freeze.
    (2) Prepare Corifact with USG 20 mL sterile water for injection before use.
    Administration
    (1) Do not mix with other drugs. Administered by separate infusion lines.

    [Storage]
    (1) Store the Corifact in the refrigerator at 2 – 8 ° C (36 – 46 ° F). Corifact is stable for 24 months until the expiration date on the box and vial label. Within the deadline, Corifact can be stored at room temperature not exceeding 25 ° C (77 ° F) for up to 6 months.
    (2) Do not put it back in the refrigerator when the product is stored at room temperature. Clearly mark the date of storage at room temperature on the label of the box.
    (3) Do not use more than the expiration date on the box and vial label, or r the end of the room storage period to see which one expires first.
    (4) In order to protect from light, store the vial in the original box. Do not freeze.
    (5) Immediately after administration. This product does not contain preservatives. This product must be used within 4 hours of preparation. Do not put the prepared solution in the refrigerator or freeze it.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • glaucoma

    Fluprostin

    【Product name】Zioptan

    [English common name]Tafluprost ophthalmic

    [Chinese common name]Fluprostin

    [English name]Tafluprost

    [Chinese other name]Fluoroprost

    [indications]Open angle type for patients with reduced intraocular pressureglaucomaOr high ocular hypertension.

    【Dosage】The recommended dose is one drop of conjunctival sac in the eye, once a day, at night. The dose should not exceed once a day as it has been shown that frequent administration of prostaglandin analogues may reduce the effects of decreased intraocular pressure.

    [Storage]Sealed and stored at 2-8 ° C (36-46 ° F). Store in the original pouch. Once the pouch is opened, the disposable container can be stored in an open foil pouch for up to 28 days at room temperature: 20-25 ° C (68-77 ° F). Moisture proof. Make a note of the date the aluminum foil bag was opened in the space provided on the pouch. Discard any unused containers 28 days after opening the bag for the first time.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Breast cancer

    Ixapilone

    【Product name】Ixempra

    [English common name]Ixabepilone

    [Chinese common name]Ixapilone

    [English name]Ipsapironum

    [Chinese other name]1-dioxide

    [Indications] IXEMPRA combined with capecitabine for the treatment of metastatic or local advancedBreast cancerPatients who are resistant to anthracyclines and taxanes, or whose cancers have taxane resistance and are further contraindicated for their anthracycline treatment. Anthracycline resistance is defined as the progressive metastatic environment during treatment or within 6 months or within 3 months of the adjuvant treatment group. Taxane resistance is defined as progression at treatment or within 12 months of adjuvant therapy or at 4 months in a metastatic environment.
    IXEMPRA is indicated for the treatment of advanced breast cancer anthracyclines, taxanes and capecitabine in patients with metastatic or local monotherapy tumor-resistant or refractory patients.

    [Usage and Dosage] The recommended dose of IXEMPRA is 40 mg / m 2 and intravenous administration for 3 hours every 3 weeks. The dose of a patient with a body surface area (BSA) greater than 2.2 m2 should be calculated according to 2.2 m2.

    [Storage] The IXEMPRA kit must be stored in a refrigerator at 2 ° C to 8 ° C (36 ° F to 46 ° F). Keep the original packaging until it is used to prevent light.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Osteoporosis in postmenopausal women

    Ibandan sodium

    [product name] BONIVA

    [English common name]Ibandronate

    [Chinese common name]Ibandronate injection

    [English name]

    [Chinese other name]

    [Indications] BONIVA is suitable for treatment and preventionOsteoporosis in postmenopausal women.

    [Usage and Dosage] The recommended dose of BONIVA for the treatment and prevention of postmenopausal osteoporosis is a 2.5 mg film-coated tablet once a day.

    [Storage] Store BONIVA at 77 °F (25 °C) or room temperature between 59 °C and 86 °F (15 °C and 30 °C).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Chronic myeloid leukemia , scleroderma

    Imatinib

    【Product name】Imatinib

    [English common name]GLEEVEC

    [Chinese common name]Imatinib

    [English name]Imatinib intermediates, imatinib

    [Chinese other name]Imatinib intermediate, imatinib

    [indications]
    Imatinib mesylate capsule: for treatmentChronic myeloid leukemia(CML) chronic phase, accelerated phase, or chronic phase after failure of alpha-interferon therapy; malignancy that cannot be surgically removed or metastasizedGastrointestinal stromal tumor (GIST)patient.
    Imatinib mesylate tablets: for the treatment of chronic chromosome patients with chronic myeloid leukemia (CML) in Philadelphia, in the blast phase, accelerated phase, or chronic phase after failure of alpha-interferon therapy.
    Adult patients for the treatment of malignant gastrointestinal stromal tumors (GIST) that cannot be removed and/or metastasized.

    【Dosage】
    Imatinib mesylate capsule: starting dose: for patients with blast crisis and accelerated phase of chronic myeloid leukemia, the recommended dose of imatinib mesylate is 600 mg/day; for chronic patients who have failed interferon therapy, and For patients with malignant gastrointestinal stromal tumors (GIST) who cannot be surgically removed or metastasized, the recommended dose is 400 mg/day, which is taken once a day. It is advisable to take the medicine at mealtime and drink a large glass of water. It should be taken continuously.
    If the blood picture permits, there is no serious adverse drug reaction, the dose can be considered to increase from 400mg / day to 600mg / day, or from 600mg / day to 800mg / day (400mg, divided into 2 times) in the following cases: disease progression, treatment A satisfactory hematologic response was not obtained after at least 3 months, and the hematologic response that had been obtained disappeared again.
    The dose must be adjusted in the following cases: if a serious non-hematologic adverse reaction (such as severe water retention) occurs during the treatment, the drug should be discontinued until the adverse reaction disappears, and then the dose is adjusted according to the severity of the adverse reaction.
    Dose adjustment in severe liver toxicity: If the bilirubin rises more than 3 times the upper limit of the normal range or the transaminase rises more than 5 times the upper limit of the normal range, the drug should be discontinued until the above indicators fall to 1.5 or 2.5 times the upper limit of the normal range. the following.
    Adjustment of dose during neutropenia or thrombocytopenia: accelerated or blast phase: if severe neutrophils and thrombocytopenia occur (neutrophils <0.5×109/L and/or platelets<10×109/L The recommended dose is reduced to 400 mg / day. If the blood cells continue to decrease for 2 weeks, further reduce the dose to 300 mg / day, if the blood cells continue to decrease for 4 weeks, it is advisable to stop the drug until neutrophils ≥ (greater than or equal to ) 1.0 × 109 / L and platelets ≥ (greater than or equal to) 20 × 109 / L. When used again, the dose is 300 mg / day.
    Patients with chronic phase after failure of α-interferon therapy: neutrophils <1.0×109/L and/or platelets <50×109/L should be discontinued, only in granulocyte ≥ (greater than or equal to) 1.5 When x109/L and platelet ≥ (greater than or equal to) 75×109/L, the dosage is 400 mg/day. If the neutrophils or platelets are reduced to the above values, the dosage will be restored. Reduced to 300 mg / day.
    Children and adolescents: There are no clinical data on the safety and efficacy of imatinib mesylate in patients under 18 years of age.
    Dosage in patients with liver failure: The plasma concentration of imatinib mesylate can be increased in patients with liver damage, so these patients should be cautious when using this drug. There is no liver damage in patients with liver damage. Nie's clinical data, no suggestion for dose adjustment.
    Renal failure and dose in elderly patients: creatinine clearance is known to decrease with age, and age has no significant effect on the pharmacokinetics of imatinib mesylate, as it has not been performed in patients with impaired renal function. Clinical trials, so it is not possible to propose a dose adjustment.
    Imatinib mesylate tablets: starting dose: The initial treatment should be performed by a physician with experience in treating chronic myelogenous leukemia or GIST.
    The product should be taken orally, and it is advisable to take the medicine while eating and drink a large glass of water. Usually adults once a day. Children and adolescents take it once or twice a day (morning and evening).
    Patients (children) who cannot swallow tablets can disperse the tablets in water or apple juice. It is recommended that pregnant and lactating women avoid contact with skin or eyes when inhaling capsules, or inhalation (see pregnant and lactating women), and wash hands immediately after touching open capsules.
    - therapeutic dose of CML patients
    adult
    The recommended dose for patients in the chronic phase is 400 mg/day, and for the blast phase and accelerated phase, it is 600 mg/day.
    As long as it is effective, it should be taken continuously.
    If the blood picture permits, there is no serious adverse drug reaction, the dose can be considered to increase from 400 mg / day to 600 mg / day, or from 600 mg / day to 800 mg / day (400 mg, orally, 2 times) Taking): The disease has not been able to obtain a satisfactory hematologic response after at least 3 months of treatment, and the hematological response has disappeared.
    Children and adolescents over 3 years old
    So far, children have limited experience in medication. According to the adult dose, the recommended daily dose is: chronic phase 260mg / m2 (maximum dose: 400mg), accelerated phase and blast phase 340mg / m2 (maximum dose: 600mg), the daily recommended dose for children, the calculated dose is generally Should be close to or around 100mg, the dose for children under 12 should generally be as close as possible or around 50mg. There is no experience in treating children under 3 years of age.
    - therapeutic dose of GIST patients
    For patients with malignant GIST who cannot be removed and/or metastasized, the recommended dose for this product is 400 mg/day.
    A satisfactory response was not obtained after treatment. If there were no adverse drug reactions, the dose could be considered to increase from 400 mg/day to 600 mg/day. Treatment time:
    For patients with GIST, the product should be treated continuously unless the condition progresses.

    [Storage]
    Imatinib mesylate capsule: should be kept below 30 °C.
    Imatinib mesylate tablets should be kept below 30 °C.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.